About GM2 Gangliosidosis, Adult-Onset
Adult-onset (chronic/subacute) GM2 gangliosidosis is a later-manifesting form of hexosaminidase deficiency (HEXA or HEXB) where residual enzyme activity allows survival to adolescence or adulthood before the accumulation of GM2 ganglioside causes neurological disease. Unlike the fatal infantile forms, adult-onset GM2 presents with spinocerebellar ataxia, motor neuron disease features, psychiatric symptoms (psychosis), and dystonia with a slowly progressive course. Psychiatric manifestations are prominent and frequently lead to delayed or missed diagnosis.
Common Clinical Features
Clinical Trial Eligibility Tips
What to know before applying to GM2 Gangliosidosis, Adult-Onset trials.
Hexosaminidase A and B enzyme activity in serum and leukocytes is required — residual activity above zero distinguishes adult from infantile forms
HEXA or HEXB variant classification (residual activity missense vs. null) and predicted enzyme activity should be documented
Psychiatric symptom history is critical — many adult GM2 patients have psychiatric diagnoses before neurological diagnosis; provide full psychiatric treatment history
Substrate reduction therapy (miglustat) trials may be available — no prior SRT is typically required, and dietary history should be documented
Patient Resources
Find recruiting GM2 Gangliosidosis, Adult-Onset trials
Search 500,000+ studies from ClinicalTrials.gov, filtered for GM2 Gangliosidosis, Adult-Onset. Updated daily.